Devon Park BioVentures
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
United States, Wayne
Devon Park BioVentures is a well known and established VC, which was founded in 2006. The primary office of this VC is located in Wayne. This investor is located in North America, United States.
The fund usually invests in rounds together with 5-6 others. Aside from Devon Park BioVentures, start-ups are often funded by Intersouth Partners, TVM Capital, Prism Venture Management and 12 other funds. The most common co-investors for the fund are Intersouth Partners, TVM Capital, Skyline Ventures and also 15 different VCs. In subsequent rounds, the fund is usually joined by TVM Capital, Prism Venture Management, Intersouth Partners, as well as 4 other investors.
Among their most successful investment fields, we have identified Biotechnology, Nanotechnology. Also, because of its portfolio diversification tendency, we can highlight 8 more industries for this fund. Moreover, a start-up needs to be 6-10 years old to get investment from this fund. The fund has no a preferred number of founders for start-ups that it invests in. If there are 4 or 5+ founders in the start-up, the probability of getting the investment is low. The country of its foundation and the country of its most frequent investments coincides - United States. ZS Pharma, Diasome, MicuRx Pharmaceuticals are among the most popular portfolio start-ups of the fund.
Besides the listed founders, we have found 2 key employees of this fund in our database.
The most exits for the fund occurred in 2014. Deals in the range of 10 - 50 millions dollars are most common for this fund. This fund was the most active in 2012. In real terms, this VC performs 20 percentage points more exits than other funds. Devon Park BioVentures is involved in 4 percentage points more than the average amount of lead investments when compared with other funds. The fund generally invests in less than 2 deals every year.
Mail Rule [rules by which you can get an email of an interesting for you fund employee, knowing only the name and surname of this employee]
Domain name: parksquarecapital.com; User name format in descending order of probability: first '.' last
Group Appearance [how often fund is operating separately from groups with shared interest]
88.9% of cases
Investments per Year [average amount of rounds in which fund participates each year]
Follow-on Index [how often fund is ready to support its portfolio startup at next rounds]
33.3% of cases
Average Multiplicator [the average ratio of the last valuation of portfolio startups to their total amount of financing raised]
Average Portfolio Company
Exit Age [the average age of portfolio startups at which they go public or become acquired]
Success / Strategy Similarity
Index [the matching between fund's investment strategy and its proved successes in the form of portfolio startups high valuations]
0.35 out of 1
Number of Unicorns [amount of portfolio companies, which were valuated at more then $1B]
By posting comments on our website you confirm and acknowledge that:
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.